Status:
COMPLETED
The Need of Revisiting to an Outpatient Clinic After the Prescription of Vonoprazan or Esomeprazole
Lead Sponsor:
Showa Inan General Hospital
Conditions:
Gastroesophageal Reflux
Eligibility:
All Genders
19-100 years
Phase:
NA
Brief Summary
After vonoprazan (20mg/day) or esomeprazole (20mg/day) for 4weeks is prescribed for patients with erosive esophagitis diagnosed by esophagogastroduodenoscopy, the number of patients who will visit our...
Detailed Description
1. Patients who have erosive esophagitis diagnosed by esophagogastroduodenoscopy is enrolled. 2. Vonoprazan (20mg/day) or esomeprazole (20mg/day) is prescribed for 4weeks the patients randomly without...
Eligibility Criteria
Inclusion
- outpatients belonging to American Society of Anesthesiologists class I or II
- patients have erosive esophagitis diagnosed by esophagogastroduodenoscopy shortly before the prescription
Exclusion
- other acid blockers are taken
Key Trial Info
Start Date :
January 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04720781
Start Date
January 21 2021
End Date
December 31 2024
Last Update
May 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Showa Inan General hospital
Komagane, Nagano, Japan, 399-4191